Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,861 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,861 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $91,637.83. Following the completion of the sale, the general counsel owned 21,225 shares in the company, valued at $679,836.75. The trade was a 11.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, June 16th, Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $43,637.15.

Stoke Therapeutics Trading Up 0.0%

Shares of STOK stock opened at $32.14 on Wednesday. The stock has a 50 day moving average of $30.81 and a 200 day moving average of $32.21. The stock has a market cap of $2.07 billion, a P/E ratio of -9.62 and a beta of 1.20. Stoke Therapeutics, Inc. has a twelve month low of $18.00 and a twelve month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The company had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. On average, research analysts predict that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on STOK shares. Guggenheim reiterated a “buy” rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Chardan Capital restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. BTIG Research restated a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. Finally, Wedbush increased their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently bought and sold shares of the company. Kestra Advisory Services LLC purchased a new position in shares of Stoke Therapeutics in the fourth quarter valued at approximately $26,000. Quantbot Technologies LP purchased a new stake in shares of Stoke Therapeutics during the second quarter worth approximately $34,000. KBC Group NV acquired a new position in Stoke Therapeutics in the 1st quarter valued at $36,000. Harbour Investments Inc. raised its stake in Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the last quarter. Finally, Western Wealth Management LLC purchased a new position in Stoke Therapeutics in the 1st quarter valued at $55,000.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.